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A B S T R A C T
Background: Elastic compression stockings (ECS) are uncomfortable to wear but
may prevent post-thrombotic syndrome (PTS). The ability to predict PTS may help clinical decision making regarding the optimal duration of ECS after deep vein
thrombosis (DVT).
Aims: Predefined endpoint analysis of the Octavia study that randomized patients who compliantly used ECS up to one year after DVT to continue or discontinue ECS
treatment. Primary aim was to identify predictors of PTS.
Methods: Patient characteristics were collected and ultrasonography was performed to assess reflux, residual thrombosis and persistent thrombus load 12months
after DVT. Multivariable analyses were performed to identify factors related to PTS.
Results: Thrombus score≥ 3, BMI≥ 26, duration of symptoms before DVT diagnosis≥ 8 days and a Villalta score of 2–4 points were statistically significant pre-
dictors of PTS. The predictive value for PTS for the assessed variables was not different between the 2 treatment groups. In the stop ECS group, 3.2% (95%CI 0.08–18)
of patients without any predictors for PTS were diagnosed with mild PTS during follow-up, and none with severe PTS, for a sensitivity of 98% (95% CI 89–100), a
specificity of 14% (95% CI 10–20), a positive predictive value of 20% (95% CI 19–22), and a negative predictive value of 97% (95% CI 81–100).
Conclusion: We identified 4 predictors of PTS occurring in the 2nd year after DVT. Our findings may be used to decide on whether to continue ECS treatment for an
additional year, after one year of compliant ECS use, keeping in mind that patients with none of the predictors will have the lowest PTS incidence.
1. Introduction
Despite adequate anticoagulation therapy, 20–50% of patients de-
velop post-thrombotic syndrome (PTS) after deep vein thrombosis
(DVT) [1]. The clinical presentation of PTS ranges from mild skin
changes to severe venous ulcers [2]. The signs and symptoms of PTS are
assessed and quantified in clinical scales such as the Villalta score,
which are used to diagnose PTS [3]. To prevent PTS, elastic compres-
sion stockings (ECS) have been suggested to be helpful when patients
wear them on a daily basis for 2 years [4,5]. Even so, stockings are
constricting, can be itchy and difficult to apply, which can lead to a low
adherence in many patients, leading to an absence of efficacy as shown
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in the SOX trial [6]. Therefore recently, two studies were performed to
investigate if a shorter duration of ECS therapy is non-inferior to con-
tinuing ECS therapy for two years. The Octavia study showed that
stopping ECS therapy in patients who did not develop PTS after a one-
year period of compliant use of ECS was not non-inferior to continuing
ECS therapy, indicating that ECS therapy should be generally continued
for at least 2 years after DVT [7]. In contrast, the IDEAL DVT study
showed that individualised therapy with compression therapy, i.e.
stopping ECS therapy after a minimal duration of 6months in case of a
Villalta score≤ 4 on two consecutive visits, was non-inferior to con-
tinuing ECS therapy for two years [8].
The ability to predict PTS may help clinical decision making with
regard to the optimal duration of ECS therapy after DVT. Extensive
proximal DVT, ipsilateral recurrent DVT and insufficient antic-
oagulation treatment have been previously described as strong risk
factors for PTS [1]. Obesity, primary venous insufficiency and residual
venous obstruction have been widely shown as being associated with
PTS as well [9–11]. Recently, three clinical prediction scores to predict
PTS after DVT were derived, consisting of these easily accessible pa-
tients characteristics assessed at time of diagnosis of DVT [12–14]. With
a substantial proportion of patients diagnosed with PTS after the first
year of DVT diagnosis, the existing scores are not suitable for making
long-term decisions on ECS therapy [1,7].
The primary aim of this predefined secondary analysis of the
Octavia study was to find independent predictors for long-term PTS
development, i.e. beyond the first year of ECS therapy, to select patients
who may stop ECS therapy after an initial treatment period of one year.
2. Methods
2.1. Patients
Data from the multicentre single blind non-inferiority randomized
controlled Octavia study were used to perform a pre-defined endpoint
analysis. In the Octavia study, adequately anticoagulated (with VKA)
patients from eight teaching hospitals in the Netherlands who were
compliant to compression therapy (knee length, ECS class III) for
12months after a symptomatic, ultrasound proven proximal DVT (po-
pliteal or more proximal vein) and were not diagnosed with PTS in
these 12months were randomized between continuation (continue-ECS
group) and cessation (stop-ECS group) of ECS therapy. Patients were
followed for 12months. The primary endpoint was the incidence of PTS
at the end of follow-up period. The diagnosis of PTS was assessed with a
full colour visual guide and defined as a Villalta score of 5 points or
more and/or the presence of a venous ulcer [15].
2.2. Assessment of predictive values
At baseline, one year after DVT diagnosis patient characteristics at
time of DVT diagnosis were collected including age, sex, BMI, smoking
status, history of VTE, trauma or surgery < 8weeks or immobilisa-
tion > 3 days before DVT, number of days of symptoms before DVT
diagnosis, cancer, thrombophilia and oral anticonception use.
Information about anticoagulant use and compliance to ECS therapy in
the first year after DVT was collected. Physical examination was per-
formed to assess the Villalta score one year after the index DVT diag-
nosis, at study entry. In the statistical analysis patients were divided in
two groups: those with 0–1 points of the Villalta score and those with
2–4 points. In addition, in three of the study sites (Diakonessenhuis
Utrecht, St Antonius Hospital Nieuwegein and University Medical
Center Utrecht), 20mL of blood was taken from each patient and stored
in a− 80 degrees fridge to assess for D-dimer, high sensitive CRP and
fibrinogen levels in one batch at the end of the study.
2.3. Ultrasound assessments
At baseline, 12 months after initial DVT diagnosis, a duplex and
colour Doppler ultrasound was performed to assess for presence of re-
flux, ‘the reflux score’, residual thrombosis and ‘the thrombus score’.
The deep venous system, i.e. the common femoral vein, superficial fe-
moral vein, profunda femoris, and popliteal veins, as well as the su-
perficial venous system, i.e. proximal and distal saphenous veins, were
evaluated for the presence of reflux and residual thrombosis. To assess
reflux, patients were examined in supine position; a compression unit
(100mmHg) was placed distal from the examined venous segment.
Flow and reflux of the valves were assessed in the longitudinal plane;
pathologic reflux was defined as reversed flow duration of> 1 s in the
proximal veins and> 0.5 s in the distal veins. This method has been
shown to be highly reproducible [16]. The reflux score was defined as
the total number of veins with pathologic reflux [17]. To assess residual
thrombosis, vein segments were examined in the transverse plane.
Residual thrombosis was defined as incomplete compressibility of a
vein segment; 1 point was scored for partial incompressibility and 2
points for complete incompressibility. The thrombus score was assessed
by counting the points for all vein segments which is a validated
method according to the International Consensus Committee on
Chronic Venous Disease [18].
2.4. Statistical analysis
Baseline characteristics of the continue-ECS group and stop-ECS
group are expressed as numbers and percentages. We had a complete
dataset for the outcome variables.< 1% of the data on the predictor
variables was missing. Therefore we performed a complete case ana-
lysis. Continuous variables were changed to categorical by selecting the
most predictive cut-off value for PTS, assessed by comparing the AUC of
the ROC curves using the method proposed by Hanley & McNeil [19].
The first primary outcome of this study was to assess the predictive
value of different clinical, biomarker and ultrasonography variables.
The predictive values of all variables are presented as odds ratios (OR)
with 95% confidence intervals (CI) calculated by univariate logistic
regression analysis for the continue-ECS group and stop-ECS group se-
parately. The second primary outcome was to find predictors to select
patients who may benefit by continuing ECS therapy for 2 years to
prevent PTS. To assess the effect modification of predictors for PTS by
wearing ECS, ECS use was inserted as interaction term in the logistic
regression analysis. Univariate tests of effect modification by ECS were
performed first. The outcome measures of this analysis were odds ratios
(OR) adjusted for wearing ECS, with statistical significance evaluated
by the Wald test. For the multivariable analysis, it was predefined based
on the sample size that only the four best predictors were run in mul-
tivariable backward conditional logistic regression analysis, again with
ECS use as interaction term, OR as outcome and the Wald test for
evaluation of statistical significance. Significant variables in multi-
variable analysis were considered to be independent predictors of PTS.
Incidence of PTS was calculated in patients from the stop-ECS group
and continue-ECS group separately without any versus with one or
more of these independent predictors. Confidence intervals around
these incidences were calculated based on the modified Wald method
[20]. Based on these incidence numbers, positive predictive value, ne-
gative predictive value and relative risk for PTS based on presence of
one or more versus none of these predictors were calculated. All sta-
tistics were performed using SPSS version 23 (IBM Corp, Armonk, NY).
A p-value < 0.05 was considered statistically significant.
3. Results
A total of 518 patients were included in the Octavia study, of whom
256 were allocated to the stop-ECS group and 262 to the continue ECS
group. From the stop-ECS group, 51 (19.9%, 95%CI 16–24) patients
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were diagnosed with PTS in the first year following randomisation,
compared to 34 (13.0%, 95%CI 9.9–17) in the continue-ECS group [7].
Relevant baseline characteristics are shown in Table 1. After locking the
database, 28% of patients turned out to be incorrectly treated with class
II (23–32mmHg) graduated active stockings instead of the intended
class III (34–46mmHg). Ultrasound and laboratory measurements are
shown in Table 2. Laboratory measurements were performed in three
study sites for a total of 135 (53%) of patients from the stop-ECS group
and 140 (53%) of patients from the continue-ECS group.
3.1. Predictors of PTS between one and two years after DVT diagnosis
With univariate logistic regression analysis, duration of symp-
toms≥ 8 days before DVT diagnosis (OR 2.9, 95% CI 1.6–5.7),
thrombophilia (OR 3.1, 95%CI 1.1–8.5), history of varicose veins at the
moment of index DVT diagnosis (OR 2.7, 95%CI 1.3–5.8) and a Villalta
score of 2–4 points 1 year after DVT diagnosis (OR 5.2, 95%CI 2.4–11)
were statistical significant predictors for PTS in the stop-ECS group
(Table 3). In the continue-ECS group, only a Villalta score of 2–4 points
(OR 3.5, 95%CI 1.5–8.4) and Fibrinogen > 4 g/L (OR 4.4, 95%CI
1.1–18) were significant predictors of PTS during follow-up. Univariate
analysis in the complete study population with ECS use as interaction
term showed no significant predictors (Appendix I), indicating that use
of ECS did not change the predictive value of any of the variables to a
relevant extent.
Multivariable analysis showed that a thrombus score≥ 3 (OR 2,
95%CI 1.1–5.1), BMI≥ 26 (OR 1.9, 95% CI 1.1–3.4), duration of
symptoms before DVT diagnosis≥ 8 days (OR 2.3, 95% 1.4–3.9), and a
Villalta score of 2–4 points (OR 4.5, 95%CI 2.5–8.2) were independent
predictors of PTS in both treatment arms of the study. Also, use of ECS
therapy itself was an independent predictor for PTS with an OR 0.52
(0.34–0.93), indicating a ~50% lower risk (Table 4). Further analyses
showed that although ECS use prevented PTS, patients with one of the
risk factors had a higher risk of PTS in both treatment arms of the
Octavia study. Sub analysis of patients that used class II and class III
ECS graduated active stockings showed similar results for univariate
and multivariable logistic regression analysis (data not shown).
3.2. Incidence of PTS in patients with one or more and without predictors
In the stop-ECS group, 31 (12%, 95%CI 9.1–16) out of 256 patients
had none of the 4 predictors identified with multivariable analysis. One
out of these 31 patients (3.2%, 95%CI 0.08–18) was diagnosed with
mild PTS (Villalta score 5) during follow-up (Table 5a). The percentage
of patients with PTS increased in the group of patients with one or more
predictors for PTS: 6.6% (95%CI 2.5–15) of patients with 1 predictor
developed PTS, 25.5% (95%CI 18–35) with 2 predictors, 28% (95% CI
17–42) with 3 predictors and 60% (95%CI 23–88) with 4 predictors.
From the 225 patients with one or more predictors for PTS 41 (18%,
95%CI 14–24) were diagnosed with mild PTS (Villalta score 5–9), 5
(2.2%, 95%CI 0.81–5.2) with moderate PTS (Villalta score 10–14) and
none with severe PTS, for a positive predictive value of 20% (95% CI
19–22), and a negative predictive value of 97% (95% CI 81–100). Re-
lative risk of PTS in patients with 1–4 predictors was 6.34 (95%CI
0.91–44).
In the continue-ECS group 21 out of 262 patients had none of the 4
predictors (8.4%; Table 5b). Three out of these 21 patients were diag-
nosed with mild PTS during follow-up (14%, 95%CI 4.1–35). The in-
cidence of PTS increased also with the number of predictors in the
continue-ECS group: incidences were 5.0% (95%CI 1.9–11) (1 pre-
dictor), 12% (95%CI 6.2–20) (2 predictors), 33% (95%CI 21–47) (3
predictors) and 43% (95%CI 16–75) (4 predictors) respectively. From
the 241 patients with one or more predictors for PTS, a total of 33 (14%
95%CI 10–19) were diagnosed with PTS during follow-up.
4. Discussion
In this pre-defined endpoint analysis from the Octavia study, we
identified 4 predictors of PTS occurring in the 2nd year after DVT,
being, duration of symptoms before DVT diagnosis≥ 8 days, BMI≥ 26,
a thrombus score≥ 3 and a Villalta score of 2–4 points, assessed 1 year
after DVT diagnosis. Patients without any of these identified risk factors
who discontinued ECS treatment had a low 3.2% incidence of mild PTS,
and none developed severe PTS. However, since the upper level of the
confidence interval was 18%, we cannot ultimately prove that the risk
of developing PTS in this cohort is negligible. Even so, with an
Table 1








Characteristics at time of the index DVT diagnosis
Age≥ 65 years 88 (34) 86(33)
Male sex 152 (59) 155 (59)
BMI≥ 246 163 (64) 162 (62)
Duration of symptoms before DVT
diagnosis≥ 8 days
84 (33) 90 (35)
History of VTE 37 (15) 38 (15)
Provoked index DVT 142 (55) 161 (62)
Cancer (active at diagnosis) 29 (11) 21 (8)
Thrombophiliaa 17 (7) 24 (9)
History of varicose veins 36 (14) 29 (11)
Current or former smoking 67 (27) 68 (26)
Index DVT in left leg 158 (62) 144 (55)
Most proximal location of DVT
Iliac vein 23 (9) 25 (10)
Common femoral vein 44 (17) 31 (12)
Superficial femoral vein 58 (23) 54 (21)
Popliteal vein 131 (51) 152 (58)
Treatment of DVT, assessed 1 year after DVT diagnosis
LMWH use ≤6 days 36 (15) 41 (16)
VKA use ≤3months 59 (24) 58 (23)
Anticoagulation treatment at baseline
(1 year after DVT)
39 (15) 37 (14)
Frequent use of ECS at year 1
(≥6 days/week)
232 (91) 249 (95)
Villalta score 2–4 points at baseline 136 (53) 145 (56)
Note: BMI: Body Mass Index, VTE: Venous thromboembolism, DVT: Deep vein
thrombosis.
a Antithrombin, protein C or S deficiency, factor V Leiden or prothrombin
mutation, presence of antiphospholipid antibodies, LMWH: low molecular
weight heparin, ECS: elastic compression stockings, CRP: c-reactive protein.
Table 2
Ultrasound and laboratory measurements assessed 1 year after the index DVT
diagnosis.





Reflux 180 (72) 174 (67)
Refluxscore ≥4a 57 (22) 53 (20)
Refluxscore, only deep veins ≥1a 145 (58) 136 (53)
Residual thrombosis 119 (46) 101 (39)
Thrombus score≥ 3a 22 (9) 24 (9)




D-dimer > 0.5mg/La 29 (21) 23 (16)
High sensitive CRP > 3mg/La 43 (32) 52 (37)
Fibrinogen > 4 g/La 12 (9) 9 (6.4)
a Continuous variables were changed to categorical by selecting the most
predictive cut-off value for PTS, assessed by comparing the AUC of the ROC
curves using the method proposed by Hanley & McNeil.
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increasing risk associated with more predictors present, our data may
be used to counsel the optimal duration of treatment in the individual
patient in clinical practice. ECS treatment may be considered to be
discontinued with few or none of the predictors present, especially in
those patients who experience ECS treatment as very uncomfortable. Of
note, only 8–12% patients had none of the predictors present, in-
dicating that the impact of this strategy would be low.
The recently published IDEAL-DVT study confirmed that it may be
possible to individualise ECS treatment. Patients were randomized to
standard duration ECS therapy (24months) or an individualised dura-
tion of ECS based on the Villalta score during follow-up [8]. All patients
were treated with ECS class III. In the individualised ECS duration
group, patients with a Villalta score≤ 4 on two consecutive visits
stopped ECS, after a minimal duration of ECS therapy of 6months.
Because the incidence of PTS was comparable between the two groups,
it was concluded that individualised therapy is non-inferior to con-
tinuing ECS for 24months. Our study provides some external validation
of the IDEAL-DVT, since we demonstrated that a higher Villalta score at
one year following an index DVT diagnosis was associated with a higher
risk of PTS.
Three other recent studies assessed clinical predictors for PTS. In the
first study, two clinical risk scores for post-thrombotic syndrome were
derived, including the variables age, BMI, varicose veins, smoking, re-
sidual vein obstruction, female sex, ileofemoral thrombosis and history
of deep vein thrombosis. One assessed the 2-year risk of post-throm-
botic syndrome at the moment of the index DVT diagnosis and the other
assessed the risk of post-thrombotic syndrome in the sub-acute phase,
6 months after diagnosis of deep vein thrombosis [12]. The Sox-PTS
score included 3 variables assessed at time of index DVT diagnosis
which were predictive for PTS: DVT in iliac vein, BMI≥ 35 and a
moderate-severe Villalta score at moment of index DVT diagnosis [14].
The third score was derived for patients aged≥ 65 years only [13]. Our
study is different from previous ones and therefore not directly
Table 3
Univariate logistic regression analysis.
Baseline features Stop ECS group
OR (95% CI), p value
Continue ECS group
OR (95% CI), p value
Age≥ 65 1.3 (0.69–2.4), 0.42 1.3 (0.62–2.8), 0.47
Male sex 1.1 (0.58–2.0), 0.82 0.98 (0.47–2.0), 0.96
BMI≥ 26 1.9 (0.94–3.7), 0.08 2.2 (0.94–5.0), 0.07
Duration of symptoms before DVT diagnosis≥ 8 days 2.9 (1.6–5.7), 0.001# 1.9 (0.92–4.0), 0.08
History of VTE 1.6 (0.71–3.6), 0.25 1.3 (0.50–3.4), 0.59
Provoked index DVT 0.97 (0.52–1.8), 0.93 2.2 (0.97–5.2), 0.06
Trauma (< 8weeks before DVT) 0.97 (0.46–2.0), 0.97 2.0 (0.91–4.3), 0.09
Surgery (< 8weeks before DVT) 1.4 (0.59–3.3), 0.45 1.2 (0.44–3.4), 0.70
Immobilisation > 6 days 1.6 (0.62–4.0), 0.35 1.5 (0.49–4.9), 0.46
Pregnant, post-partum or use of hormonal replacement therapy 0.73 (0.33–1.6), 0.44 0.94 (0.40–2.2), 0.89
Cancer (active at diagnosis) 0.61 (0.20–1.8), 0.38 1.6 (0.52–5.2), 0.40
Thrombophiliaa 3.1 (1.1–8.5), 0.03# 1.4 (0.44–4.3), 0.59
History of varicose veins 2.7 (1.3–5.8), 0.01# 1.9 (0.71–5.1), 0.20
Current or former smoking 1.3 (0.64–2.5), 0.50 1.4 (0.65–3.1), 0.39
Index DVT in left leg 1.2 (0.62–2.2), 0.62 1.2 (0.58–2.5), 0.63
Most proximal location of DVT
Iliac vein 0.48 (0.14–1.7), 0.27 0.85 (0.23–3.1), 0.81
Common femoral vein 0.61 (0.25–1.5), 0.28 1.2 (0.42–3.5), 0.74
Superficial femoral vein 0.67 (0.31–1.5), 0.33 0.64 (0.23–1.8), 0.39
Popliteal vein (reference)
Treatment of DVT
LMWH use ≤6 days 1.3 (0.58–3.0), 0.50 0.94 (0.34–2.6), 0.94
VKA use ≤3months 0.79 (0.37–1.7), 0.55 1.8 (0.81–3.9), 0.15
Anticoagulation treatment at baseline (1 year after DVT) 1.8 (0.81–3.9), 0.15 1.1 (0.38–2.9), 0.92
Frequent use of ECS at year 1 (≥6 days/week) 1.1 (0.36–3.4), 0.85 0.71 (0.15–3.4), 0.67
Villalta T=0 2–4 points 5.2 (2.4–11), 0.00# 3.5 (1.5–8.4), 0.005#
Ultrasound measurements
Reflux 1.1 (0.60–2.1), 0.88 1.1 (0.51–2.5), 0.77
Refluxscore total≥ 4 1.1 (0.53–2.3), 0.81 1.8 (0.80–4.0), 0.16
Refluxscore, only deep veins≥ 1 1.0 (0.53–1.9), 0.91 1.2 (0.54–2.6), 0.69
Residual thrombosis 1.1 (0.62–2.1), 0.68 1.0 (0.49–2.2), 0.95
Thrombus score≥ 3 2.0 (0.77–5.2), 0.15 2.5 (0.92–6.8), 0.07
Laboratory measurements
D-dimer > 0.5mg/L 1.0 (0.40–2.53), 0.98 1.0 (0.31–3.3), 0.97
High sensitive CRP > 3mg/L 1.7 (0.77–3.8), 0.19 1.55 (0.64–3.76), 0.34
Fibrinogen >4 g/L 0.87 (0.22–3.4), 0.85 4.4 (1.1–18), 0.04#
Note:
# p < 0.05 BMI: Body Mass Index, VTE: Venous thromboembolism, DVT: Deep vein thrombosis.
a Antithrombin, protein C or S deficiency, factor V Leiden or prothrombin mutation, presence of antiphospholipid antibodies, LMWH: low molecular
weight heparin, ECS: elastic compression stockings, CRP: c-reactive protein.
Table 4
Multivariable backward conditional logistic regression analysis, adjusted for
ECS use.
Variablesa β Odds ratio (95%CI)
Use of ECS −0.577 0.52 (0.34–0.93)
Thrombus score≥ 3 0.877 2.4 (1.1–5.1)
BMI≥ 26 0.645 1.9 (1.1–3.4)
Duration of symptoms before DVT
diagnosis≥ 8 days
0.843 2.3 (1.4–3.9)
Villalta T= 0 2–4 1.504 4.5 (2.5–8.2)
a Variables entered on step 1: Use of ECS, Thrombus score≥ 3, BMI > 25,
Duration of symptoms before DVT diagnosis≥ 8 days, Villalta T=0≥ 2, Use
of ECS* Thrombus score≥ 3, Use of ECS*BMI > 25, Use of ECS* Duration of
symptoms before DVT diagnosis≥ 8 days, Use of ECS* Villalta T= 0≥ 2.
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comparable, since we studied predictors for PTS occurring in the second
year after DVT.
Most of the predictors identified in the current analysis have been
associated with a higher risk of PTS in prior studies. Residual throm-
bosis for example was found to be associated with a 3-fold higher risk of
PTS in a large study including 869 consecutive patients with proximal
DVT who were assessed for residual thrombosis by ultrasound after
three months of treatment [11].The pathophysiologic mechanism of
residual thrombosis causing PTS has also been widely described. Re-
sidual thrombosis causes damage to the venous valves, which leads to
valve incompetence, reflux and venous hypertension, finally resulting
in an absence of pressure decrease in the venous system during walking,
the latter being one of the main pathophysiological mechanisms of PTS
[2]. The second predictor, obesity, has been more often described as
well [9,21,22].
The third predictor, duration of symptoms before DVT diag-
nosis> 8 days has not been previously described. However, this delay
in diagnosing DVT is associated with a longer delay in initiation of
adequate anticoagulant treatment. It has been shown earlier that ab-
sence of anticoagulant treatment strongly increases the risk of PTS [23],
as does subtherapeutic use of vitamin K antagonists [24,25].
The fourth identified predictor was a Villalta score of 2–4 points
with PTS defined as a Villalta score≥ 5. The likely associations explain
this finding. First, it is plausible that patients with pre-clinical PTS one
year after a DVT diagnosis are more likely to have progressive symp-
toms and meet the diagnostic criteria of PTS than patients with no signs
of PTS at all. Second, a Villalta score of 2–4 points may not only be
caused by preclinical PTS, but may also be due to venous insufficiency
or other causes. The latter has been shown to be associated with higher
risk of PTS [10,26].
Interestingly, in univariate analysis, with popliteal vein thrombosis
as reference, iliac vein thrombosis showed an OR of 0.48 (95% CI
0.14–1.7) and 0.85 (95% CI 0.23–3.1) in the stop-ECS group and
continue-ECS group for PTS respectively. This is in contrast with pre-
vious studies where iliac vein thrombosis was an important risk factor
for PTS [22]. Since in this study only patients who did not develop PTS
during the first year after DVT were included, we hypothesise that iliac
vein thrombosis could mainly be a risk factor for early PTS within the
first year after a DVT diagnosis.
The biomarkers that were measured in 275 patients from this study,
e.g. CRP, D-dimer and fibrinogen, showed no predictive value for PTS.
Only a fibrinogen level of> 4 g/dl was associated with PTS in the
continue-ECS group. Previous studies have evaluated the association
with D-dimer, CRP, fibrinogen and PTS [9,27,28]. One study assessed
D-dimer levels one year after DVT in 228 patients. The authors of that
study reported a significantly higher D-dimer level in patients with PTS
as opposed to those without PTS, although after multivariate adjust-
ment, D-dimer was not found to be independently predictive of PTS
[27]. In contrast, CRP levels > 5mg/L did show a strong and in-
dependent association with PTS for an OR of 8.0 (95%CI 2.4–26). An
association between fibrinogen and PTS has not been found in previous
studies and should be further investigated in future studies [29].
The main strength of this study is that this represents a pre-defined
endpoint analysis from a randomized controlled trial. A limitation of
this study is that laboratory tests were not performed in all patients.
Further, only patients who already used ECS compliantly during the
first year after PTS diagnosis were included, and patients who already
developed PTS during the first year after DVT were excluded.
Therefore, the results of this study cannot be generalised to unselected
patients with DVT. Moreover, our findings require external validation
before they may be incorporated in clinical practice. This is mainly
necessary because of the multiple analysis steps were taken to identify
the predictors. Nonetheless, results of the IDEAL study and the Octavia
study both strongly suggest that it should be possible to better in-
dividualise ECS therapy in the future. It remains to be determined
which clinical, radiological and biochemical variables are to be
Table 5












0 predictorsa 30 (97) 1 (3.2) 0 0 1 (3.2)
1 predictor 71 (93) 5 (6.6) 0 0 5 (6.6)
2 predictors 70 (74) 22 (23) 2 (2.1) 0 24 (26)
3 predictors 36 (72) 12 (24) 2 (4.0) 0 14 (28)












0 predictorsa 18 (86) 3 (14) 0 0 3 (14)
1 predictor 96 (95) 4 (4.0) 1 (1.0) 0 5 (5.0)
2 predictors 77 (89) 9 (10) 0 1 (1.2) 10 (12)
3 predictors 31 (67) 14 (30) 1 (2.2) 0 15 (33)












0 predictorsa 48 (92) 4 (8) 0 0 4 (8)
1 predictor 167 (94) 9 (5) 1 (0.6) 0 10 (6)
2 predictors 147 (81) 31 (17) 2 (1) 1 (0.6) 34 (19)
3 predictors 67 (70) 26 (27) 3 (3) 0 29 (30)
4 predictors 6 (50) 5 (42) 1 (8) 0 6 (50)
a Predictors: thrombus score≥ 3, duration of symptoms before DVT diagnosis≥ 8 days, Villalta score≥ 2, BMI≥ 26.
G.C. Mol et al. Thrombosis Research 173 (2019) 35–41
39
included in the optimal risk stratification tool for this purpose.
In conclusion, this study shows that a thrombus score≥ 3,
BMI≥ 26, duration of symptoms before DVT diagnosis≥ 8 days, and a
Villalta score 2–4 were independent predictors of PTS in patients with
proximal DVT who completed 1 year of compliant ECS use and were not
diagnosed with PTS in the first year after DVT. The incidence of PTS in
patients without any of these predictors was lower than in patients with
one or more of these predictors present. Our findings may be used to
individualise ECS treatment after one year of compliant ECS use.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.thromres.2018.11.002.
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